Today we have the pleasure of speaking with Josh Bartch, the CEO of Mydecine, a research & development company with a special interest in psilocybin and psychoactive treatments. We discuss the origins of their work, their team, and current research and practices in the field.Topics covered:Mydecine's mission and commitment to human benefit via fungal discoveryPsilocybin treatment for PTSD and other mental health concernsMachine-learning based drug discoveryFormulation and commercialization of psychedelic therapeutics The deficiencies in chemical compounds in psilocybe mushroomsVarietals of psilocybin-containing mushrooms Collaborative and intern opportunities at Mydecine’s facilitiesDescribing new compounds in functional mushroomsBureaucracy of importing and researching psychedelic mushrooms Bioavailability of psilocybin Managing ethical clinical researchShow notes:Mydecine website: https://www.mydecine.com/Josh Bartch LinkedIn: https://www.linkedin.com/in/josh-bartch-a5361b96MindLeap app: https://mindleap.health/